Press Releases

04.14.2025

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

04.10.2025

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24

04.01.2025

European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

03.18.2025

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

03.11.2025

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

02.24.2025

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.13.2025

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

02.12.2025

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

02.10.2025

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

02.04.2025

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

02.03.2025

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

01.28.2025

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium